Apr 16, 2020 4:01 pm EDT Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Mar 30, 2020 7:30 am EDT Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease
Feb 14, 2020 7:00 am EST Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019
Feb 10, 2020 7:00 am EST Immunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Dec 19, 2019 8:00 am EST Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation